Testosterone replacement therapy and the risk of prostate cancer. Is there a link? (Q36310652)

13 August 2017

1 reference

title

Testosterone replacement therapy and the risk of prostate cancer. Is there a link? (English)

1 reference

13 August 2017

1 reference

1 reference

1 reference

Barqawi A

1

1 reference

PubMed ID

16281043

13 August 2017

Crawford ED

series ordinal

2

1 reference

13 August 2017

10 November 2005

1 reference

International Journal of Impotence Research

13 August 2017

1 reference

13 August 2017

18

1 reference

13 August 2017

4

1 reference

13 August 2017

323-328

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901418

13 August 2017

0 references

cites work

Mutation of the androgen receptor causes oncogenic transformation of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Sex steroid hormone metabolism and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Androgen replacement therapy and prostate safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Serum sex hormones and measures of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

The proliferative function of basal cells in the normal and hyperplastic human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Occult prostate cancer in men with low serum testosterone levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Pretreatment serum testosterone level as a predictive factor of pathological stage in localized prostate cancer patients treated with radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Low serum testosterone level predicts worse response to endocrine therapy in Japanese patients with metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Hormonal predictors of prostate cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Serum testosterone levels in African-American and white men undergoing prostate biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Racial differences in prostate androgen levels in men with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Diagnostic significance of digital rectal examination and transrectal ultrasonography in men with prostate-specific antigen levels of 4 NG/ML or less

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Testosterone replacement therapy after primary treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

The correlation between pretreatment serum hormone levels and treatment outcome for patients with prostatic cancer and bony metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

Leydig cell function in normal men: effect of age, life-style, residence, diet, and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901418

7 January 2021

Identifiers

DOI

10.1038/SJ.IJIR.3901418

1 reference

13 August 2017

1 reference

PubMed ID

16281043